Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion Biotech A/S (EVAX) is a clinical-stage biotechnology company leveraging proprietary AI platforms to advance immunotherapies for cancer and infectious diseases. This page serves as the definitive source for verified corporate announcements, research milestones, and strategic developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory filings, and technology innovations. Our curated collection includes press releases on AI-driven drug discovery, partnership announcements, and financial reports, all organized for efficient tracking of the company's trajectory.
Key content areas include updates from Evaxion's PIONEER and EDEN platform pipelines, oncology vaccine developments, and infectious disease research breakthroughs. The repository is maintained to reflect the company's evolving position at the intersection of artificial intelligence and immunotherapy.
Bookmark this page for streamlined access to Evaxion's official communications. Check regularly for new developments in personalized cancer vaccines and AI-optimized antigen discovery.
Evaxion (NASDAQ: EVAX) announced new preclinical data for its multi-component cytomegalovirus vaccine program EVX-V1 on November 20, 2025. Using its AI-Immunology™ platform, the company identified novel CMV antigens that induce specific immune responses, inhibit viral infection and reduce cell-to-cell spread in cellular and animal models. Evaxion also reports an AI-optimized pre-fusion glycoprotein B (gB) antigen with enhanced CMV neutralization versus a traditional gB antigen. Evaxion is continuing preclinical optimization and is exploring strategic partnerships to support non-clinical and clinical advancement.
Evaxion (NASDAQ: EVAX) announced its 2026 financial calendar on November 12, 2025. Key scheduled dates include:
- March 5, 2026 – Business update and full year 2025 financial results
- April 16, 2026 – Annual General Meeting
- May 7, 2026 – Business update and Q1 2026 financial results
- August 20, 2026 – Business update and Q2 2026 financial results
- November 19, 2026 – Business update and Q3 2026 financial results
The company said the full calendar is available on its website and provided investor relations contact details.
Evaxion (NASDAQ: EVAX) presented new biomarker and immune data for its AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting on November 7, 2025.
Data from the phase 2 trial—conducted in combination with Merck's anti-PD-1 therapy KEYTRUDA—report longitudinal blood sampling that characterized circulating T-cell subsets before, during and after treatment. In analyzed patient subsets, clinical responses were accompanied by a rapid and sustained induction of EVX-01-specific T cells. The release complements previously presented two-year clinical efficacy data from the same trial.
Evaxion (NASDAQ: EVAX) reported Q3 2025 results and a business update on November 6, 2025. Key clinical and corporate highlights include appointment of Dr Helen Tayton-Martin as CEO effective Nov 24, 2025, presentation of two‑year phase 2 data for personalized cancer vaccine EVX‑01 showing a 75% ORR (12/16) with four complete responses and 92% still responding at two years, and out‑licensing of bacterial vaccine EVX‑B3 to MSD with a $7.5M option fee and potential future payments up to $592M. Financially, Q3 revenue was $7.5M, net income $4.6M, cash of $10.6M as of Sep 30, 2025, and cash runway extended to the second half of 2027.
Evaxion (NASDAQ: EVAX) announced EVX-04, an AI-designed precision therapeutic cancer vaccine candidate for acute myeloid leukemia (AML) developed using its AI‑Immunology™ platform. EVX-04 targets multiple non-conventional ERV tumor antigens from the dark genome that are present in tumors but absent in normal tissue and is designed as an off‑the‑shelf vaccine for immediate use after diagnosis. New preclinical data showing strong T‑cell responses and cancer cell killing will be presented orally at the American Society of Hematology (ASH) Annual Meeting on December 6, 2025.
Presentation: Abstract #278, Emerging Tools session, Hyatt Regency Ballroom, 2:00pm ET; presenter Rasmus Villebro.
Evaxion (NASDAQ: EVAX) corrected its announcement date and will provide a business update and report third quarter 2025 financial results on November 6, 2025, before Nasdaq market open. Executive Management will host a live conference call and webcast the same day at 14:30 CET / 08:30 EST to present results and take questions.
The event is free and open to the public; attendees should register in advance to receive dial-in numbers and a unique PIN for verbal questions. The call is accessible 15 minutes early and a webcast recording will be posted on the company website shortly after the event. Contact: Mads Kronborg, Vice President Investor Relations & Communication, +45 53 54 82 96, mak@evaxion.ai
Evaxion (NASDAQ: EVAX) will provide a business update and report its third quarter 2025 financial results on Friday, October 31, 2025 before Nasdaq open. Management will host a conference call and webcast the same day at 14:30 CET / 08:30 EST to present results and take questions. The event is free and open to the public; participants must register in advance to receive dial-in numbers and a unique PIN for verbal questions. The call can be accessed 15 minutes before the start. A webcast link will be provided and a recording will be posted on the company website shortly after the event. Investor relations contact: Mads Kronborg, Vice President Investor Relations & Communication.
Evaxion (NASDAQ: EVAX) raised $7.2 million through an at-the-market share sale ($4.5M) and investor warrant exercises ($2.7M), and reports a total cash inflow of $14.7M since the end of Q2 2025. Combined with a $7.5M license payment from MSD for EVX-B3 in September 2025, Evaxion says it now has cash to fund operations and R&D into the second half of 2027 (extended from H1 2027).
The company reports an expected operational cash spend of $14M in 2025, a reduction of outstanding warrants by 1.0M to 2.8M total, and a weighted average warrant exercise price of $10.94. A debt-to-equity conversion reduced prior debt by $4.1M.
Evaxion (NASDAQ: EVAX) appointed Dr Helen Tayton-Martin as Chief Executive Officer, effective 24 November 2025. She will simultaneously resign from Evaxion’s Board.
Dr Tayton-Martin holds a Ph.D. in molecular immunology and an MBA, co-founded Adaptimmune and spent 17 years there in senior operating and business roles overseeing transatlantic growth, partnerships and financing through a Nasdaq IPO. Evaxion highlighted recent commercial progress including the out-license of EVX-B3 to MSD and presentation of EVX-01 data at ESMO.
Birgitte Rønø will return to her role as Chief Scientific Officer. Jens Bitsch-Norhave will join the Board as adviser and observer and intends to seek election at the Annual General Meeting in 2026.
Evaxion (NASDAQ: EVAX) reported two-year phase 2 results for its AI-designed personalized cancer vaccine EVX-01 in advanced melanoma on October 17, 2025.
Key outcomes: ORR 75% (12/16 patients), including 4 complete responses; 92% of patients still responding at 24 months; tumor reduction in 15/16 patients; 81% of vaccine targets induced T-cell responses; 54% experienced deepened responses; treatment was well tolerated. Data presented at ESMO 2025; webinar scheduled October 22, 2025.
FAQ
What is the current stock price of Evaxion AS (EVAX)?
What is the market cap of Evaxion AS (EVAX)?
